Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial
Primary resultResult — go to the resultWin ratio 1.01 95% CI 0.90–1.13Authors' conclusion
The addition of dapagliflozin to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.
Study context
- Population
- Adults with unplanned intensive care unit (ICU) admission and at least 1 organ dysfunction (respiratory, cardiovascular, or kidney), 22 ICUs in Brazilrandomized
- Participants
- 507 adults
- Comparison
- Dapagliflozin 10 mg plus standard care vs standard care alone
- Dapagliflozinn = 248
- Controln = 259reference
- Primary endpoint
- Hierarchical composite of:
- Hospital mortality
- Initiation of kidney replacement therapy
- ICU LOS
- Follow-up
- 28 days
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Primary result
As reported in the abstract
Win ratio
1.01
95% CI 0.90–1.13
P = 0.89
Dapagliflozin vs Control
win ratio 1.01 (95% CI 0.90–1.13); P = 0.89
Secondary outcomes
Use of kidney replacement therapy
- Use of kidney replacement therapy — Probability of benefit for dapagliflozin (highest among secondary outcomes; bayesian)
- 0.90
Original publication
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial. JAMA. Published 6 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →